“7X tested.” “8X tested.” “Made in the USA.” The badges keep getting bigger, but the most important questions remain: Who made the product? Which batch was tested? And does the report match the vial being sold today?
PEPTUESDAY 1•1•1 1 thing we’re researching. 1 thing worth remembering. 1 thought for your week. This edition is a little longer than our usual three-minute read because transparency deserves more than a slogan. 1 thing we’re researching What peptide testing claims actually tell us I want to have an honest conversation about something increasingly common in the grey-market peptide industry: marketing claims that sound impressive but leave important questions unanswered. This is not an attempt to suggest that Platform Labs is perfect or that every larger company is dishonest. It is simply a call for clearer language and better traceability. I would rather tell customers a less glamorous truth than sell them a polished claim that the evidence cannot support. That begins with the word reseller . Platform Labs is a reseller. We do not synthesize peptides in our own manufacturing facility. We purchase products, test the batches we receive, document those results, and resell them. Many grey-market peptide storefronts operate under the same basic model, even when their branding suggests otherwise. Legitimate peptide manufacturing does occur in the United States. But a U.S. website, domestic mailing address, American laboratory report, or U.S.-based fulfillment center does not necessarily mean the peptide was synthesized here. The Federal Trade Commission says an unqualified “Made in USA” claim generally means that all or virtually all significant processing, ingredients, and components are domestic. Companies making that claim should have reliable evidence supporting it. “Tested in the USA” and “shipped from the USA” are different from “manufactured in the USA.” If a seller claims its peptides are domestically manufactured, customers should be able to ask: Which facility synthesized the peptide? Can that facility be independently verified? Can the manufacturing record be connected to the lot being sold? Is the company describing synthesis, filling, labeling, testing, or fulfillment? Those are different steps, and the language should make the distinction clear. The problem with “7X tested” and “8X tested” These phrases are everywhere. At this pace, someone may soon unveil a “27X tested” badge large enough to be seen from space. The tests behind those numbers can be valuable. A testing panel may examine identity, purity, peptide content, sterility, endotoxins, heavy metals, residual solvents, or other potential contaminants. The important distinction is between testing breadth and testing coverage . Testing breadth tells us how many characteristics were examined in a sample. Testing coverage tells us how frequently inventory is sampled and whether the report corresponds to the batch currently being sold. Seven assays on one vial represent seven categories of analysis—not seven separately tested batches. That is why a COA should be connected to an identifiable sample and lot. A useful report should include: The laboratory name A report or verification number The date of analysis The analytical methods used The specifications and results A batch, lot, or sample identifier The seller should then be able to connect that report to the corresponding inventory. A product name is not a batch. “BPC-157” is not a batch. “Retatrutide 30 mg” is not a batch. When new inventory arrives, customers should be able to determine which report accompanies it. The volume question One of the most important questions customers can ask is: How often is the company testing compared with how much inventory it purchases? If a company sells thousands of vials while displaying a single report, customers should ask how much inventory that report represents, whether the inventory has changed, and whether newer batch-specific reports are available. I cannot speak to what another company may test privately. But customers should not have to fill gaps in public documentation with assumptions created by polished branding. What Platform Labs does Platform Labs intentionally purchases small quantities—generally one or two kits of ten vials at a time. We test one vial from each kit or purchase batch and maintain a verified COA for every material lot purchased for resale. When a new batch is purchased and tested, its corresponding report is added to our website. That is why customers may see multiple COAs for the same product. Small-batch purchasing creates a shorter, more traceable connection between the tested sample and the inventory being sold. This approach costs more per vial and limits how quickly we can scale. It is also the approach I am most comfortable putting my name behind. The heart behind this conversation My concern is not that testing badges are always meaningless. My concern is that branding can create an impression far broader than the documentation shows. “7X tested” may describe seven legitimate analyses. “8X tested” may describe eight. Customers should still be able to see which batch was examined and whether that batch corresponds to the product currently available. The same clarity should apply to domestic-manufacturing claims. Synthesis, testing, labeling, storage, and shipping are separate activities and should be described accurately. I am not asking anyone to trust Platform Labs merely because I wrote a confident newsletter. Look at our reports. Match the dates and identifiers. Verify the laboratory record when possible. Ask how much inventory each sample represents. Real transparency is not saying, “Trust us.” It is showing our work. 1 thing worth remembering Seven tests on one vial are not seven batches tested. The number of assays describes the breadth of the analysis. Batch-specific documentation connects that analysis to the product being sold. When reviewing a peptide COA, ask three questions: What exactly was tested? Which batch did it come from? Is that the batch being sold today? The biggest badge on the internet cannot replace clear answers. 1 thought for your week “Sunlight is said to be the best of disinfectants.” — Louis D. Brandeis Transparency is not about tearing other companies down. It is about respecting people enough to communicate clearly and support our claims with evidence. That is the kind of company I want Platform Labs to become—not necessarily the loudest or largest reseller, but one willing to show its work and tell the truth plainly. Thank you for giving me a few extra minutes this Tuesday. I believe this conversation matters. — Larry Platform Labs The Platform for Peptides